Protocol Ledger

NCT04752358 · Phase II · TERMINATED

ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

Interventional Phase II clinical trial protocol NCT04752358 sponsored by Adaptimmune in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-15 Enrollment: 3 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04752358
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04752358
Protocol FieldVerified Registry Value
NCT IdentifierNCT04752358
Consolidated Lead SponsorAdaptimmune
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment3 participants (ACTUAL)
Registered Start Date2021-09-15
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI